Lex Van Der Ploeg

Lex Van Der Ploeg has a diverse work experience in various roles and companies. Lex is currently serving as the President, Chairman, and CEO of VDP LLC dba RIFFIT since June 2019. Lex is also the Director at DeuteRx since September 2019 and a Consultant at Rhythm Pharmaceuticals Inc. since July 2019.

In the past, Lex Van Der Ploeg has held the position of Managing Director at VDP LLC, an independent consulting agency focused on guiding Research and Development for the Biotechnology and Pharmaceutical Industries and private investors, starting from August 2011. Lex also served as a Strategy and Scientific Advisor at DeuteRx, LLC from December 2012.

Furthermore, Lex Van Der Ploeg has been involved with Retrotope, Inc./Biojiva as a Board Observer and Consultant since December 2012. Lex was an Interim Chairman of the Board of Directors at Retrotope, Inc. from August 2020 to November 2020. Lex also held the role of Sr Advisor at INKEF Capital from June 2018 to March 2022.

Additionally, Lex Van Der Ploeg is the Founder, President, and Chairman of the Board of Directors of Yao The Bard. LLC dba RIFFIT since January 2021. Lex previously served as the Founder, President, Chairman of the Board of Directors, and CEO of Yao The Bard, LLC dba RIFFIT from June 2019 to December 2020.

Overall, Lex Van Der Ploeg has a wealth of experience in leadership, consulting, and advisory roles within the biotechnology, pharmaceutical, and investment industries.

Lex Van Der Ploeg obtained a Ph.D. degree in Enzymology, Genetics, and Biochemistry. Lex pursued their doctoral studies from 1972 to 1984 at both the Universiteit Van Amsterdam and The Netherlands Cancer Institute as well as the University of Amsterdam.